These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 30066286)

  • 21. Differential effects of inhibitors of the PI3K/mTOR pathway on the expansion and functionality of regulatory T cells.
    Huijts CM; Santegoets SJ; Quiles Del Rey M; de Haas RR; Verheul HM; de Gruijl TD; van der Vliet HJ
    Clin Immunol; 2016 Jul; 168():47-54. PubMed ID: 27189717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
    Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.
    Nölting S; Rentsch J; Freitag H; Detjen K; Briest F; Möbs M; Weissmann V; Siegmund B; Auernhammer CJ; Aristizabal Prada ET; Lauseker M; Grossman A; Exner S; Fischer C; Grötzinger C; Schrader J; Grabowski P;
    PLoS One; 2017; 12(8):e0182852. PubMed ID: 28800359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Molecular mechanisms of resistance to phosphatidyl inositol 3-kinase inhibitors in triple-negative breast cancer cells].
    Zhang WL; Ma WJ; Chen S; Wu XZ; Zhang HR; Zhang JH
    Zhonghua Zhong Liu Za Zhi; 2016 Aug; 38(8):578-88. PubMed ID: 27531477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
    Liu Y; Chen X; Luo Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumors: rationale and efficacy.
    Van Looy T; Wozniak A; Floris G; Sciot R; Li H; Wellens J; Vanleeuw U; Fletcher JA; Manley PW; Debiec-Rychter M; Schöffski P
    Clin Cancer Res; 2014 Dec; 20(23):6071-82. PubMed ID: 25316817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Everolimus reduces postoperative arthrofibrosis in rabbits by inducing autophagy-mediated fibroblast apoptosis by PI3K/Akt/mTOR signaling pathway.
    Liu Y; Zhang Z; Yan L; Li X; Zhang J; Zhang X; Zhu D; Sun Y; Jiang Q
    Biochem Biophys Res Commun; 2020 Nov; 533(1):1-8. PubMed ID: 32919704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.
    Park E; Park J; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
    Int J Oncol; 2012 Apr; 40(4):1259-66. PubMed ID: 22159814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas.
    Anderson JL; Park A; Akiyama R; Tap WD; Denny CT; Federman N
    PLoS One; 2015; 10(9):e0133610. PubMed ID: 26402468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel pan PI3K inhibitor-induced apoptosis in APL cells correlates with suppression of telomerase: An emerging mechanism of action of BKM120.
    Bashash D; Delshad M; Safaroghli-Azar A; Safa M; Momeny M; Ghaffari SH
    Int J Biochem Cell Biol; 2017 Oct; 91(Pt A):1-8. PubMed ID: 28834761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts.
    Heits N; Heinze T; Bernsmeier A; Kerber J; Hauser C; Becker T; Kalthoff H; Egberts JH; Braun F
    BMC Cancer; 2016 May; 16():322. PubMed ID: 27206490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors.
    Vandamme T; Beyens M; de Beeck KO; Dogan F; van Koetsveld PM; Pauwels P; Mortier G; Vangestel C; de Herder W; Van Camp G; Peeters M; Hofland LJ
    Br J Cancer; 2016 Mar; 114(6):650-8. PubMed ID: 26978006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia.
    Pereira JK; Machado-Neto JA; Lopes MR; Morini BC; Traina F; Costa FF; Saad ST; Favaro P
    Eur J Cancer; 2015 Sep; 51(14):2076-85. PubMed ID: 26238016
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats.
    Netland IA; Førde HE; Sleire L; Leiss L; Rahman MA; Skeie BS; Miletic H; Enger PØ; Goplen D
    J Neurooncol; 2016 Aug; 129(1):57-66. PubMed ID: 27283525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blockade efficacy of MEK/ERK-dependent autophagy enhances PI3K/Akt inhibitor NVP-BKM120's therapeutic effectiveness in lung cancer cells.
    Ren H; Guo H; Thakur A; Zhang S; Wang T; Liang Y; Shi P; Gao L; Liu F; Feng J; Chen T; Yang T; Shang D; Liu JJ; Xu F; Chen M
    Oncotarget; 2016 Oct; 7(41):67277-67287. PubMed ID: 27572309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma.
    Zang C; Eucker J; Liu H; Coordes A; Lenarz M; Possinger K; Scholz CW
    Leuk Lymphoma; 2014 Feb; 55(2):425-34. PubMed ID: 23721513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
    Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
    Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas.
    Lee M; Wiedemann T; Gross C; Leinhäuser I; Roncaroli F; Braren R; Pellegata NS
    Clin Cancer Res; 2015 Jul; 21(14):3204-15. PubMed ID: 25838390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abrogation of Autophagy by Chloroquine Alone or in Combination with mTOR Inhibitors Induces Apoptosis in Neuroendocrine Tumor Cells.
    Avniel-Polak S; Leibowitz G; Riahi Y; Glaser B; Gross DJ; Grozinsky-Glasberg S
    Neuroendocrinology; 2016; 103(6):724-37. PubMed ID: 26619207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.